| Press releases

Formycon Expands Board and Appoints Pharma Top Manager Dr. Stefan Glombitza as Chief Operating Officer

Dr. Stefan Glombitza will join Formycon on October 1, 2016 and add his strengths to the Management Board. He will in future act as Chief Operating Officer (COO), focusing especially on the company’s operational development activities


German Equity Forum 2016

German Equity Forum 2016, November 21 – 23; Frankfurt/Main

Financial reports

Half-Year Report 2015

Published on 14. September 2015

  • buchner_en
  • pipeline-en-teaser
  • Foto_MedicineMaker_Powerlist
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.